YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

<div>Identification of low immunogenicity in EGFR-mutant NSCLC. Overlapping mutant genes distributed in the mutation count group (a) and fraction genome altered group (b). Genes with the highest frequency in the fraction genome altered groups (c) and mutation count groups (d).</div>

Canadian Respiratory Journal

fig2

Figure 2

Figure 2: YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer 